BofA raised the firm’s price target on PTC Therapeutics (PTCT) to $87 from $76 and keeps a Buy rating on the shares. The firm’s survey of 20 neurologists and geneticist who treat PKU patients on early Sephience usage trends indicates “high community interest,” says the analyst. The firm, which models Q3 Sephience sales of $7M and FY25 sales of $26.4M, continues to view this as “a blockbuster opportunity” and models peak sales of $1.5B, calling PTC one of its top picks for 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Optimistic Buy Rating for PTC Therapeutics Driven by Strong Demand and Promising Sales Projections for Sephience
- Strong Buy Rating for PTC Therapeutics Driven by Sephience Launch and Strategic Growth Opportunities
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Hold Rating on PTC Therapeutics Amid Competitive Gene Therapy Landscape and High-Risk Outlook
- PTC shares to see pressure on ‘compelling’ uniQure data, says Citi